Cite
Lee J, Galloway R, Grandjean G, et al. Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. J Cancer. 2015;6(12):1306-19doi: 10.7150/jca.13266.
Lee, J., Galloway, R., Grandjean, G., Jacob, J., Humphries, J., Bartholomeusz, C., Goodstal, S., Lim, B., Bartholomeusz, G., Ueno, N. T., & Rao, A. (2015). Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. Journal of Cancer, 6(12), 1306-19. https://doi.org/10.7150/jca.13266
Lee, Jangsoon, et al. "Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer." Journal of Cancer vol. 6,12 (2015): 1306-19. doi: https://doi.org/10.7150/jca.13266
Lee J, Galloway R, Grandjean G, Jacob J, Humphries J, Bartholomeusz C, Goodstal S, Lim B, Bartholomeusz G, Ueno NT, Rao A. Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. J Cancer. 2015 Oct 28;6(12):1306-19. doi: 10.7150/jca.13266. eCollection 2015. PMID: 26640591; PMCID: PMC4643087.
Copy
Download .nbib